Hypereosinophilic Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major hypereosinophilic syndrome markets are expected to exhibit a CAGR of 9.32% during 2024-2034.
The hypereosinophilic syndrome market has been comprehensively analyzed in IMARC's new report titled "Hypereosinophilic Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Hypereosinophilic syndrome is a rare and heterogeneous group of disorders characterized by persistently elevated levels of eosinophils, a form of white blood cell, in the blood and tissues. This condition can lead to tissue damage and organ dysfunction. The symptoms of the ailment can differ widely and often depend on the affected site. Some common indications associated with this disease include fatigue, fever, skin rashes, chest pain, difficulty breathing, gastrointestinal disturbances, neurological abnormalities, etc. The diagnosis of hypereosinophilic syndrome involves a thorough clinical evaluation, including a detailed medical history and physical examination. Blood tests are also performed to confirm the elevated eosinophil levels and rule out various other potential causes. Further imaging studies, such as X-rays, ultrasounds, and CT scans, might be conducted to assess organ involvement in patients. Additionally, a biopsy of affected tissues may be performed to evaluate the extent of eosinophil infiltration and any associated damage.
The increasing cases of genetic abnormalities that can lead to elevated production of eosinophil, resulting in their infiltration into numerous organs and causing inflammation and damage, are primarily driving the hypereosinophilic syndrome market. In addition to this, the inflating utilization of effective therapeutics, such as tyrosine kinase inhibitors, glucocorticoids, and monoclonal antibodies targeting interleukin-5 (IL-5), to manage the disease and prevent its complications is also creating a positive outlook for the market. Moreover, the widespread adoption of adjunctive approaches like bone marrow transplantation and hematopoietic stem cell therapy is further bolstering the market growth. These interventions aim to restore normal hematopoiesis and mitigate the harmful effects of eosinophilic infiltration. Apart from this, the rising usage of targeted therapies, since they are directed at specific genetic mutations responsible for the disorder, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of supportive care measures, such as nutritional guidance and lifestyle adjustments to minimize indications and enhance the quality of life for individuals suffering from the ailment is also augmenting the market growth. Furthermore, the escalating application of gene-editing technologies, like CRISPR-Cas9, wherein faulty genetic sequences can be precisely modified to restore normal cellular functions, is expected to drive the hypereosinophilic syndrome market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the hypereosinophilic syndrome market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for hypereosinophilic syndrome and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the hypereosinophilic syndrome market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the hypereosinophilic syndrome market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the hypereosinophilic syndrome market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape
This report also provides a detailed analysis of the current hypereosinophilic syndrome marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report
Market Insights
How has the hypereosinophilic syndrome market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the hypereosinophilic syndrome market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the hypereosinophilic syndrome market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of hypereosinophilic syndrome across the seven major markets?
What is the number of prevalent cases (2018-2034) of hypereosinophilic syndrome by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of hypereosinophilic syndrome by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with hypereosinophilic syndrome across the seven major markets?
What is the size of the hypereosinophilic syndrome patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of hypereosinophilic syndrome?
What will be the growth rate of patients across the seven major markets?
Hypereosinophilic Syndrome: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for hypereosinophilic syndrome drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the hypereosinophilic syndrome market?
What are the key regulatory events related to the hypereosinophilic syndrome market?
What is the structure of clinical trial landscape by status related to the hypereosinophilic syndrome market?
What is the structure of clinical trial landscape by phase related to the hypereosinophilic syndrome market?
What is the structure of clinical trial landscape by route of administration related to the hypereosinophilic syndrome market?
The hypereosinophilic syndrome market has been comprehensively analyzed in IMARC's new report titled "Hypereosinophilic Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Hypereosinophilic syndrome is a rare and heterogeneous group of disorders characterized by persistently elevated levels of eosinophils, a form of white blood cell, in the blood and tissues. This condition can lead to tissue damage and organ dysfunction. The symptoms of the ailment can differ widely and often depend on the affected site. Some common indications associated with this disease include fatigue, fever, skin rashes, chest pain, difficulty breathing, gastrointestinal disturbances, neurological abnormalities, etc. The diagnosis of hypereosinophilic syndrome involves a thorough clinical evaluation, including a detailed medical history and physical examination. Blood tests are also performed to confirm the elevated eosinophil levels and rule out various other potential causes. Further imaging studies, such as X-rays, ultrasounds, and CT scans, might be conducted to assess organ involvement in patients. Additionally, a biopsy of affected tissues may be performed to evaluate the extent of eosinophil infiltration and any associated damage.
The increasing cases of genetic abnormalities that can lead to elevated production of eosinophil, resulting in their infiltration into numerous organs and causing inflammation and damage, are primarily driving the hypereosinophilic syndrome market. In addition to this, the inflating utilization of effective therapeutics, such as tyrosine kinase inhibitors, glucocorticoids, and monoclonal antibodies targeting interleukin-5 (IL-5), to manage the disease and prevent its complications is also creating a positive outlook for the market. Moreover, the widespread adoption of adjunctive approaches like bone marrow transplantation and hematopoietic stem cell therapy is further bolstering the market growth. These interventions aim to restore normal hematopoiesis and mitigate the harmful effects of eosinophilic infiltration. Apart from this, the rising usage of targeted therapies, since they are directed at specific genetic mutations responsible for the disorder, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of supportive care measures, such as nutritional guidance and lifestyle adjustments to minimize indications and enhance the quality of life for individuals suffering from the ailment is also augmenting the market growth. Furthermore, the escalating application of gene-editing technologies, like CRISPR-Cas9, wherein faulty genetic sequences can be precisely modified to restore normal cellular functions, is expected to drive the hypereosinophilic syndrome market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the hypereosinophilic syndrome market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for hypereosinophilic syndrome and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the hypereosinophilic syndrome market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the hypereosinophilic syndrome market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the hypereosinophilic syndrome market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape
This report also provides a detailed analysis of the current hypereosinophilic syndrome marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report
Market Insights
How has the hypereosinophilic syndrome market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the hypereosinophilic syndrome market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the hypereosinophilic syndrome market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of hypereosinophilic syndrome across the seven major markets?
What is the number of prevalent cases (2018-2034) of hypereosinophilic syndrome by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of hypereosinophilic syndrome by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with hypereosinophilic syndrome across the seven major markets?
What is the size of the hypereosinophilic syndrome patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of hypereosinophilic syndrome?
What will be the growth rate of patients across the seven major markets?
Hypereosinophilic Syndrome: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for hypereosinophilic syndrome drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the hypereosinophilic syndrome market?
What are the key regulatory events related to the hypereosinophilic syndrome market?
What is the structure of clinical trial landscape by status related to the hypereosinophilic syndrome market?
What is the structure of clinical trial landscape by phase related to the hypereosinophilic syndrome market?
What is the structure of clinical trial landscape by route of administration related to the hypereosinophilic syndrome market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 HYPEREOSINOPHILIC SYNDROME - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (?2018-2023?) and Forecast (?2024-2034?)
4.4 Market Overview (?2018-2023?) and Forecast (?2024-2034?)
4.5 Competitive Intelligence
5 HYPEREOSINOPHILIC SYNDROME - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 HYPEREOSINOPHILIC SYNDROME - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (?2018-2023?)
7.2.2 Epidemiology Forecast (?2024-2034?)
7.2.3 Epidemiology by Age (???2018-2034)
7.2.4 Epidemiology by Gender (???2018-2034)
7.2.5 Diagnosed Cases (???2018-2034)
7.2.6 Patient Pool/Treated Cases (???2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (?2018-2023?)
7.3.2 Epidemiology Forecast (?2024-2034?)
7.3.3 Epidemiology by Age (???2018-2034)
7.3.4 Epidemiology by Gender (???2018-2034)
7.3.5 Diagnosed Cases (???2018-2034)
7.3.6 Patient Pool/Treated Cases (???2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (?2018-2023?)
7.4.2 Epidemiology Forecast (?2024-2034?)
7.4.3 Epidemiology by Age (???2018-2034)
7.4.4 Epidemiology by Gender (???2018-2034)
7.4.5 Diagnosed Cases (???2018-2034)
7.4.6 Patient Pool/Treated Cases (???2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (?2018-2023?)
7.5.2 Epidemiology Forecast (?2024-2034?)
7.5.3 Epidemiology by Age (???2018-2034)
7.5.4 Epidemiology by Gender (???2018-2034)
7.5.5 Diagnosed Cases (???2018-2034)
7.5.6 Patient Pool/Treated Cases (???2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (?2018-2023?)
7.6.2 Epidemiology Forecast (?2024-2034?)
7.6.3 Epidemiology by Age (???2018-2034)
7.6.4 Epidemiology by Gender (???2018-2034)
7.6.5 Diagnosed Cases (???2018-2034)
7.6.6 Patient Pool/Treated Cases (???2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (?2018-2023?)
7.7.2 Epidemiology Forecast (?2024-2034?)
7.7.3 Epidemiology by Age (???2018-2034)
7.7.4 Epidemiology by Gender (???2018-2034)
7.7.5 Diagnosed Cases (???2018-2034)
7.7.6 Patient Pool/Treated Cases (???2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (?2018-2023?)
7.8.2 Epidemiology Forecast (?2024-2034?)
7.8.3 Epidemiology by Age (???2018-2034)
7.8.4 Epidemiology by Gender (???2018-2034)
7.8.5 Diagnosed Cases (???2018-2034)
7.8.6 Patient Pool/Treated Cases (???2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (?2018-2023?)
7.9.2 Epidemiology Forecast (?2024-2034?)
7.9.3 Epidemiology by Age (???2018-2034)
7.9.4 Epidemiology by Gender (???2018-2034)
7.9.5 Diagnosed Cases (???2018-2034)
7.9.6 Patient Pool/Treated Cases (???2018-2034)
8 HYPEREOSINOPHILIC SYNDROME - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 HYPEREOSINOPHILIC SYNDROME - UNMET NEEDS
10 HYPEREOSINOPHILIC SYNDROME - KEY ENDPOINTS OF TREATMENT
11 HYPEREOSINOPHILIC SYNDROME - MARKETED PRODUCTS
11.1 List of Hypereosinophilic Syndrome Marketed Drugs Across the Top 7 Markets
11.1.1 Nucala (Mepolizumab) - GlaxoSmithKline
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Gleevec (Imatinib) - Novartis
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report
12 HYPEREOSINOPHILIC SYNDROME - PIPELINE DRUGS
12.1 List of Hypereosinophilic Syndrome Pipeline Drugs Across the Top 7 Markets
12.1.1 Benralizumab - AstraZeneca/Kyowa Kirin
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Depemokimab - GlaxoSmithKline
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Dexpramipexole - Areteia Therapeutics
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Etokimab - AnaptysBio
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report
13. HYPEREOSINOPHILIC SYNDROME - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. HYPEREOSINOPHILIC SYNDROME – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 HYPEREOSINOPHILIC SYNDROME - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Hypereosinophilic Syndrome - Market Size
15.2.1.1 Market Size (?2018-2023?)
15.2.1.2 Market Forecast (?2024-2034?)
15.2.2 Hypereosinophilic Syndrome - Market Size by Therapies
15.2.2.1 Market Size by Therapies (?2018-2023?)
15.2.2.2 Market Forecast by Therapies (?2024-2034?)
15.3 Market Scenario - United States
15.3.1 Hypereosinophilic Syndrome - Market Size
15.3.1.1 Market Size (?2018-2023?)
15.3.1.2 Market Forecast (?2024-2034?)
15.3.2 Hypereosinophilic Syndrome - Market Size by Therapies
15.3.2.1 Market Size by Therapies (?2018-2023?)
15.3.2.2 Market Forecast by Therapies (?2024-2034?)
15.3.3 Hypereosinophilic Syndrome - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Hypereosinophilic Syndrome - Market Size
15.4.1.1 Market Size (?2018-2023?)
15.4.1.2 Market Forecast (?2024-2034?)
15.4.2 Hypereosinophilic Syndrome - Market Size by Therapies
15.4.2.1 Market Size by Therapies (?2018-2023?)
15.4.2.2 Market Forecast by Therapies (?2024-2034?)
15.4.3 Hypereosinophilic Syndrome - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Hypereosinophilic Syndrome - Market Size
15.5.1.1 Market Size (?2018-2023?)
15.5.1.2 Market Forecast (?2024-2034?)
15.5.2 Hypereosinophilic Syndrome - Market Size by Therapies
15.5.2.1 Market Size by Therapies (?2018-2023?)
15.5.2.2 Market Forecast by Therapies (?2024-2034?)
15.5.3 Hypereosinophilic Syndrome - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Hypereosinophilic Syndrome - Market Size
15.6.1.1 Market Size (?2018-2023?)
15.6.1.2 Market Forecast (?2024-2034?)
15.6.2 Hypereosinophilic Syndrome - Market Size by Therapies
15.6.2.1 Market Size by Therapies (?2018-2023?)
15.6.2.2 Market Forecast by Therapies (?2024-2034?)
15.6.3 Hypereosinophilic Syndrome - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Hypereosinophilic Syndrome - Market Size
15.7.1.1 Market Size (?2018-2023?)
15.7.1.2 Market Forecast (?2024-2034?)
15.7.2 Hypereosinophilic Syndrome - Market Size by Therapies
15.7.2.1 Market Size by Therapies (?2018-2023?)
15.7.2.2 Market Forecast by Therapies (?2024-2034?)
15.7.3 Hypereosinophilic Syndrome - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Hypereosinophilic Syndrome - Market Size
15.8.1.1 Market Size (?2018-2023?)
15.8.1.2 Market Forecast (?2024-2034?)
15.8.2 Hypereosinophilic Syndrome - Market Size by Therapies
15.8.2.1 Market Size by Therapies (?2018-2023?)
15.8.2.2 Market Forecast by Therapies (?2024-2034?)
15.8.3 Hypereosinophilic Syndrome - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Hypereosinophilic Syndrome - Market Size
15.9.1.1 Market Size (?2018-2023?)
15.9.1.2 Market Forecast (?2024-2034?)
15.9.2 Hypereosinophilic Syndrome - Market Size by Therapies
15.9.2.1 Market Size by Therapies (?2018-2023?)
15.9.2.2 Market Forecast by Therapies (?2024-2034?)
15.9.3 Hypereosinophilic Syndrome - Access and Reimbursement Overview
16 HYPEREOSINOPHILIC SYNDROME - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 HYPEREOSINOPHILIC SYNDROME MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 HYPEREOSINOPHILIC SYNDROME MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 HYPEREOSINOPHILIC SYNDROME - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (?2018-2023?) and Forecast (?2024-2034?)
4.4 Market Overview (?2018-2023?) and Forecast (?2024-2034?)
4.5 Competitive Intelligence
5 HYPEREOSINOPHILIC SYNDROME - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 HYPEREOSINOPHILIC SYNDROME - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (?2018-2023?)
7.2.2 Epidemiology Forecast (?2024-2034?)
7.2.3 Epidemiology by Age (???2018-2034)
7.2.4 Epidemiology by Gender (???2018-2034)
7.2.5 Diagnosed Cases (???2018-2034)
7.2.6 Patient Pool/Treated Cases (???2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (?2018-2023?)
7.3.2 Epidemiology Forecast (?2024-2034?)
7.3.3 Epidemiology by Age (???2018-2034)
7.3.4 Epidemiology by Gender (???2018-2034)
7.3.5 Diagnosed Cases (???2018-2034)
7.3.6 Patient Pool/Treated Cases (???2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (?2018-2023?)
7.4.2 Epidemiology Forecast (?2024-2034?)
7.4.3 Epidemiology by Age (???2018-2034)
7.4.4 Epidemiology by Gender (???2018-2034)
7.4.5 Diagnosed Cases (???2018-2034)
7.4.6 Patient Pool/Treated Cases (???2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (?2018-2023?)
7.5.2 Epidemiology Forecast (?2024-2034?)
7.5.3 Epidemiology by Age (???2018-2034)
7.5.4 Epidemiology by Gender (???2018-2034)
7.5.5 Diagnosed Cases (???2018-2034)
7.5.6 Patient Pool/Treated Cases (???2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (?2018-2023?)
7.6.2 Epidemiology Forecast (?2024-2034?)
7.6.3 Epidemiology by Age (???2018-2034)
7.6.4 Epidemiology by Gender (???2018-2034)
7.6.5 Diagnosed Cases (???2018-2034)
7.6.6 Patient Pool/Treated Cases (???2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (?2018-2023?)
7.7.2 Epidemiology Forecast (?2024-2034?)
7.7.3 Epidemiology by Age (???2018-2034)
7.7.4 Epidemiology by Gender (???2018-2034)
7.7.5 Diagnosed Cases (???2018-2034)
7.7.6 Patient Pool/Treated Cases (???2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (?2018-2023?)
7.8.2 Epidemiology Forecast (?2024-2034?)
7.8.3 Epidemiology by Age (???2018-2034)
7.8.4 Epidemiology by Gender (???2018-2034)
7.8.5 Diagnosed Cases (???2018-2034)
7.8.6 Patient Pool/Treated Cases (???2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (?2018-2023?)
7.9.2 Epidemiology Forecast (?2024-2034?)
7.9.3 Epidemiology by Age (???2018-2034)
7.9.4 Epidemiology by Gender (???2018-2034)
7.9.5 Diagnosed Cases (???2018-2034)
7.9.6 Patient Pool/Treated Cases (???2018-2034)
8 HYPEREOSINOPHILIC SYNDROME - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 HYPEREOSINOPHILIC SYNDROME - UNMET NEEDS
10 HYPEREOSINOPHILIC SYNDROME - KEY ENDPOINTS OF TREATMENT
11 HYPEREOSINOPHILIC SYNDROME - MARKETED PRODUCTS
11.1 List of Hypereosinophilic Syndrome Marketed Drugs Across the Top 7 Markets
11.1.1 Nucala (Mepolizumab) - GlaxoSmithKline
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Gleevec (Imatinib) - Novartis
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report
12 HYPEREOSINOPHILIC SYNDROME - PIPELINE DRUGS
12.1 List of Hypereosinophilic Syndrome Pipeline Drugs Across the Top 7 Markets
12.1.1 Benralizumab - AstraZeneca/Kyowa Kirin
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Depemokimab - GlaxoSmithKline
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Dexpramipexole - Areteia Therapeutics
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Etokimab - AnaptysBio
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report
13. HYPEREOSINOPHILIC SYNDROME - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. HYPEREOSINOPHILIC SYNDROME – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 HYPEREOSINOPHILIC SYNDROME - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Hypereosinophilic Syndrome - Market Size
15.2.1.1 Market Size (?2018-2023?)
15.2.1.2 Market Forecast (?2024-2034?)
15.2.2 Hypereosinophilic Syndrome - Market Size by Therapies
15.2.2.1 Market Size by Therapies (?2018-2023?)
15.2.2.2 Market Forecast by Therapies (?2024-2034?)
15.3 Market Scenario - United States
15.3.1 Hypereosinophilic Syndrome - Market Size
15.3.1.1 Market Size (?2018-2023?)
15.3.1.2 Market Forecast (?2024-2034?)
15.3.2 Hypereosinophilic Syndrome - Market Size by Therapies
15.3.2.1 Market Size by Therapies (?2018-2023?)
15.3.2.2 Market Forecast by Therapies (?2024-2034?)
15.3.3 Hypereosinophilic Syndrome - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Hypereosinophilic Syndrome - Market Size
15.4.1.1 Market Size (?2018-2023?)
15.4.1.2 Market Forecast (?2024-2034?)
15.4.2 Hypereosinophilic Syndrome - Market Size by Therapies
15.4.2.1 Market Size by Therapies (?2018-2023?)
15.4.2.2 Market Forecast by Therapies (?2024-2034?)
15.4.3 Hypereosinophilic Syndrome - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Hypereosinophilic Syndrome - Market Size
15.5.1.1 Market Size (?2018-2023?)
15.5.1.2 Market Forecast (?2024-2034?)
15.5.2 Hypereosinophilic Syndrome - Market Size by Therapies
15.5.2.1 Market Size by Therapies (?2018-2023?)
15.5.2.2 Market Forecast by Therapies (?2024-2034?)
15.5.3 Hypereosinophilic Syndrome - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Hypereosinophilic Syndrome - Market Size
15.6.1.1 Market Size (?2018-2023?)
15.6.1.2 Market Forecast (?2024-2034?)
15.6.2 Hypereosinophilic Syndrome - Market Size by Therapies
15.6.2.1 Market Size by Therapies (?2018-2023?)
15.6.2.2 Market Forecast by Therapies (?2024-2034?)
15.6.3 Hypereosinophilic Syndrome - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Hypereosinophilic Syndrome - Market Size
15.7.1.1 Market Size (?2018-2023?)
15.7.1.2 Market Forecast (?2024-2034?)
15.7.2 Hypereosinophilic Syndrome - Market Size by Therapies
15.7.2.1 Market Size by Therapies (?2018-2023?)
15.7.2.2 Market Forecast by Therapies (?2024-2034?)
15.7.3 Hypereosinophilic Syndrome - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Hypereosinophilic Syndrome - Market Size
15.8.1.1 Market Size (?2018-2023?)
15.8.1.2 Market Forecast (?2024-2034?)
15.8.2 Hypereosinophilic Syndrome - Market Size by Therapies
15.8.2.1 Market Size by Therapies (?2018-2023?)
15.8.2.2 Market Forecast by Therapies (?2024-2034?)
15.8.3 Hypereosinophilic Syndrome - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Hypereosinophilic Syndrome - Market Size
15.9.1.1 Market Size (?2018-2023?)
15.9.1.2 Market Forecast (?2024-2034?)
15.9.2 Hypereosinophilic Syndrome - Market Size by Therapies
15.9.2.1 Market Size by Therapies (?2018-2023?)
15.9.2.2 Market Forecast by Therapies (?2024-2034?)
15.9.3 Hypereosinophilic Syndrome - Access and Reimbursement Overview
16 HYPEREOSINOPHILIC SYNDROME - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 HYPEREOSINOPHILIC SYNDROME MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 HYPEREOSINOPHILIC SYNDROME MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
